Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Probiotics and Low-FODMAP diet tested for chronic pelvic pain relief

NCT ID NCT07149519

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at whether a special low-FODMAP diet and probiotics can reduce chronic pelvic pain in women who have both endometriosis and irritable bowel syndrome (IBS). Researchers will compare three groups: one getting the diet plus a placebo, one getting the diet plus probiotics, and one eating their usual diet. The goal is to see if these approaches improve pain and quality of life over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
probiotics (Lactobacillus spp) and low-FODMAP diet
What this could lead to
If it works, this could offer a simple, non-drug way to reduce pelvic pain and improve quality of life for women with both endometriosis and IBS.
What could go wrong
This is a small, early-stage trial with only 74 participants, so results may not apply to everyone. The diet and probiotics may not help all women, and the study does not test for long-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 74 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 50 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women between 18 and 50 years of age who wish to participate in the clinical trial; 2. Willingness to voluntarily participate in the study and accept randomization to any of the three treatment arms; 3. Participating exclusively in this clinical trial during the study period; 4. Signing the Informed Consent Form (ICF) approved by the Research Ethics Committee (CEP) and CONEP Exclusion Criteria: 1. Chronic, severe, or uncompensated clinical conditions, such as: malnutrition (BMI \<18); insulin-dependent diabetes (types 1 or 2); uncontrolled hypertension; lung disease such as asthma or other chronic obstructive pulmonary disease; hematologic and liver diseases; advanced-stage chronic kidney disease (grades 3, 4, and 5); metabolic disorders; and immunosuppression; 2. Clinical conditions of the gastrointestinal tract that cause IBS-like symptoms, such as: inflammatory bowel disease (Chron's disease, ulcerative colitis), microscopic colitis, celiac disease, and lactose intolerance; 3. Endometriosis requiring surgical treatment during the study period; 4. Severe eating disorders, such as: bulimia, anorexia nervosa, and binge-eating disorder; 5. Chronic use of any medication with potential interaction with probiotics, the intestinal microbiota, or the natural progression of the disease in the last 6 months (such as probiotics, antibiotics, antifungals, antihistamines, digestive medications, or treatments for constipation or diarrhea); 6. Patients who already consume healthy foods or are on a restrictive diet more than four days a week, which may affect the evaluation results; 7. Patients whose stool protopastological examination is altered; 8. Inability to use oral medication; 9. Pregnancy or lactation; 10. History of alcohol or drug dependence; 11. Smoking in the last three years; 12. Inability to cooperate with investigators due to cognitive impairment or mental state.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bowels irritable are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Letícia Ferracini Lenharo Hayashi

    RECRUITING

    Catanduva, São Paulo, 15800-050, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.